AMPHAmphastar Pharmaceuticals, Inc.

$25.14+2.5% 1Y

Is it growing?

Watch

Growth is fading: earnings down −37% year on year and operating margin narrowing (−9.5 points).

2 to watch, 1 neutral
Revenue trend+1% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +14% a year.

Earnings trend−37% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction−9.5 points operating

Trailing-twelve-month operating margin, 15.6% now against 25.0% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is AMPH growing?

Amphastar Pharmaceuticals, Inc.'s revenue has grown 11% a year over three years, and grown 14% a year over five, with earnings per share falling 4.5% a year.

+11%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +12% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate
+14%

Revenue growth, 5-year rate · +11% over three · growth has slowed since the five-year average

Earnings per share, 3-year rate
−4.5%

Earnings per share, 3-year rate · revenue +11% · earnings lagged revenue: the growth is costing something

Years of annual history on file
14

Years of annual history on file · FY2012 to FY2025, as filed

Details›
Revenue FY2021
$438M
Revenue FY2022
$499M
Revenue FY2023
$644M
Revenue FY2024
$732M
Revenue FY2025
$720M

Annual income statements as filed with the SEC.